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Background: CASTLE (Carcinoma showing thymus-like elements) is a rare malignant neoplasm of the thyroid
resembling lymphoepithelioma-like and squamous cell carcinoma of the thymus with different biological behaviour
and a better prognosis than anaplastic carcinoma of the thyroid.
Methods: We retrospectively investigated 6 cases of this very rare neoplasm in order to investigate the mutational
status of KRAS, EGFR, PDGFR-α and KIT, as well as the immunohistochemical expression pattern of CD117, EGFR and
COX-2, and possibly find new therapeutic targets.
Results: Diagnosis was confirmed by a moderate to strong expression of CD5, CD117 and CK5/6, whereas thyroglobulin,
calcitonin and TTF-1 were negative in all cases. Tumors were also positive for COX-2 and in nearly all cases for
EGFR. In four cases single nucleotide polymorphisms (SNPs) could be detected in exon 12 of the PDGFR-α gene
(rs1873778), in three cases SNPs were found in exon 20 of the EGFR gene (rs1050171). No mutations were found
in the KIT and KRAS gene.
Conclusions: All tumors showed a COX-2 expression as well as an EGFR expression except for one case and a
wild-type KRAS status. No activating mutations in the EGFR, KIT and PDGFR-α gene could be detected. Our data
may indicate a potential for targeted therapies, but if these therapeutic strategies are of benefit in CASTLE remains to
be determined.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1658499296115016
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Carcinoma showing thymus-like elements (CASTLE) is
a rare malignant tumor of the thyroid gland. It was first
described by Miyauchi et al. in 1985 as “intrathyreoidal
epithelial thymoma” [1], is thought to arise from ectopic
thymic tissue within the thyroid gland or rudimentary
branchial pouches along the thymic line and was named
CASTLE by Chan and Rosai in 1991 [2]. CASTLE-tumors
belong to a group of ectopic tumors of thymic differenti-
ation: Ectopic hamartomatous thymoma, ectopic cervical
thymoma, spindle epithelial tumors with thymus like dif-
ferentiation (SETTLE) and carcinoma showing thymic-* Correspondence: Lothar.Veits@klinikum-bayreuth.de
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unless otherwise stated.like elements (CASTLE). Although CASTLE shows some
tendencies for squamous differentiation, it has newly been
adopted as an independent entity by the recent WHO
classification [3]. In contrast to ectopic thymomas, SET-
TLE and CASTLE are always malignant and therefore the
exact diagnosis is crucial in consideration of prognosis and
treatment. CASTLE tumors have characteristic clinical and
histological features. They are tumor of the adults in the
fifth decade of life and often invade the adjacent soft tissue.
Metastases into the regional lymph nodes are common.
The largest study yet performed comprised 25 cases [4].
According to this study it is likely that some thyroid can-
cers, especially those with squamous differentiation may
have been treated incorrectly based on an improper classi-
fication. For our study we collected 6 cases of this rare ma-
lignancy and evaluated possible therapeutic options.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In our study we included 6 patients suffering from
CASTLE, 3 women and 3 men, diagnosed between 1997
and 2007. The median age was 60 years ranging from 30
to 68 years.
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMA) were performed from the
paraffin-wax-embedded blocks of the tumor speci-
mens. A tissue arrayer device (Beecher Instruments,
Sun Prairie, WI, USA) was used. All the investigated
cases were reviewed and representative tumor areas
were marked in the corresponding paraffin wax blocks,
of which at least two were sampled. The diameter of
the cylinders was 1.2 mm. For immunohistochemistry
5 μm sections on poly-L-lysine-coated slides were used
after drying in an oven, followed by dewaxing and per-
oxidase blocking with 1% H2O2. The specificity of im-
munostaining was tested by replacing primary antisera
with normal rabbit serum. No additional pre-treatment
procedure for antigen retrieval was done. The immunor-
eactions were performed with the following primary mono-
clonal antibodies: Anti-COX-2 (monoclonal rabbit IgG;
Santa Cruz, USA; 1:50), anti-CD5 (monoclonal mouse IgG;
Novocastra, Leica Microsystems, Wetzlar, Germany; 1:25),
anti-TTF-1 (monoclonal mouse, IgG, SPT24; Menarini,
Florence, Italy; 1:100), anti-CK 5/6 (monoclonal mouse
IgG, M7237; Dako Cytomation, Glostrup, Denmark; 1:50),
anti-Ki67 (monoclonal mouse IgG, K-2, Zytomed, Berlin,
Germany; ready-to-use). Primary polyclonal antibodies
used were: CD117 (polyclonal rabbit, A4502; Dako Cyto-
mation, Glostrup, Denmark; 1:50), anti-thyroglobulin (poly-
clonal rabbit, A0251; Dako Cytomation, Glostrup, Denmark;
1:80000) and anti-calcitonin (polyclonal rabbit, A0576;
Dako Cytomation, Glostrup, Denmark; 1:4000). After wash-
ing steps signal detection was performed (EnVision +
system-HRP, AEC, Dako Hamburg, Germany; 1:200)
followed by counterstaining in hemalaun. Detection of
EGFR was performed with the EGFR pharmDX kit
(Dako Hamburg, Germany) according to manufacturer’s
instructions.
The presence of clearly visible dark brown precipita-
tion was considered as immunoreaction, evaluated by a
score for staining intensity (0: no staining; 1: weak; 2:
moderate; 3: strong reaction intensity).
Mutational analysis of KIT, PDGR-α, EGFR, KRAS
Cores of tumor tissue selected from regions on corre-
spondent Hematoxylin-Eosin slides were manually punched
out from the donor blocks. DNA was extracted from
paraffin-embedded tissue sections using EZ1 DNA tis-
sue Kit (Qiagen, Hilden Germany) after pre-treatment
with proteinase K (Qiagen, Hilden Germany). 150 ng
DNA were used for PCR amplification and all PCRreactions were run at a final volume of 25 μl (Red Jump
MasterMix, Sigma-Aldrich). Exons 9, 11, 13 and 17 of
KIT, exons 10, 12, 14 und 18 of PDGFR-α, exons 18, 19,
20 and 21 of EGFR and exons 2 and 3 of KRAS were
evaluated for the presence of mutations by PCR ampli-
fication and direct sequencing. The primer pairs used
for PCR amplification and direct sequencing are shown
in Table 1. After estimation of DNA concentration by
spectroscopy (GeneQuant) relevant exons were ampli-
fied by PCR under standard conditions with an anneal-
ing temperature of 50°C for Exon 17 (KIT), 55°C for
Exon 2 and 3 (KRAS), Exon 9 (KIT) and Exon 18
(PDGFR), 60°C for Exon 18, 19, 20 and 21 (EGFR) and
Exon 11 and 13 (KIT) as well as Exon 10, 12 and 14
(PDGFR) with the corresponding primers. The PCR
products were then separated on agarose gel containing
ethidiumbromide and visualized under ultraviolet light.
Afterward PCR products were purified using high pure
PCR product purification kit (Roche Diagnostics, Penzberg,
Germany) and then sent to Qiagen (Hilden, Germany) for
sequencing according to Sanger method.Ethical approval
This study was approved by the ethics committee of the
University Hospital Heidelberg (reference number: 206/
2005).Results
Clinical and histological characteristics
The primary symptom was a palpable node in 2 patients
and an adenomatous goitre as well as a paresis of the re-
current nerve in 1 case, respectively. In 3 cases no case
history was available. 5 tumours were located in the thy-
roid and 1 was partially extrathyroidal, the latter with
the majority of the tumor mass in the thyroid gland.
Local tumor stage was T2 in one case, T3 in 3 cases,
the remaining cases T4. In 3 cases no lymph nodes were
affected, 3 patients already developed lymph node me-
tastases. All cases underwent curative hemi- or total thy-
roidectomy. 5 patients received postoperative radiotherapy,
1 received a combined radio- and chemotherapy. The me-
dian time of follow-up observation was 18.5 months, with
a range from 2 to 36 months. During this time, 1 patient
developed local recurrence 2 months after primary oper-
ation and underwent a second tumorectomy with bilateral
neck dissection and transsternal lymphadenectomy. The
remaining patients were recurrence-free (see Table 2). By
histology the resected specimen showed fibrous septa with
lobulation and surrounding tumor islands of various size
(see Figure 1C + F). Especially the peripheral tumor tissue
was infiltrated by small lymphocytes (see Figure 1A,B,
D,E). Scattered blood vessels were found, surrounded
by fibrous connective tissue.
Table 1 Primer sequences for KIT, PDGR, EGFR, KRAS PCR amplification
KIT9F 5′GCC ACA TCC CAA GTG TTT TAT G KIT9R 5′GAG CCT AAA CAT CCC CTT AAA TTG
KIT11F 5′CCA GAG TGC TCT AAT GAC TG KIT11R 5′AGC CCC TGT TTC ATA CTG AC
KIT13F 5′CTT GAC ATC AGT TTG CCA GTT GT KIT13R 5′GAC AGA CAA TAA AAG GCA GCT TG
KIT14F 5′CTC ACC TTC TTT CTA ACC TTT TCT T KIT14R 5′CCC ATG AAC TGC CTG TCA AC
KIT17F 5′ATG GTT TTC TTT TCT CCT CC KIT17R 5′TAC ATT ATG AAA GTC ACA GG
PDGFRA10F 5′GGC CCT ATA CTT AGG CCC TTT T PDGFRA10R 5′TGT CCT GAC TGT TGA GGA ACT
PDGFRA12F 5′CTC TGG TGC ACT GGG ACT TT PDGFRA12R 5′GCA AGG GAA AAG GGA GTC TT
PDGFRA14F 5′TCT GAG AAC AGG AAG TTG GTA GC PDGFRA14R 5′CCA GTG AAA ATC CTC ACT CCA
PDGFRA18F 5′TCT TGC AGG GGT GAT GCT AT PDGFRA18R 5′AGA AGC AAC ACC TGA CTT TAG AGA TTA
EGFR18F 5′GCT GAG GTG ACC CTT GTC TC EGFR18R 5′ACA GCT TGC AAG GAC TCT GG
EGFR19F 5′GCT GGT AAC ATC CAC CCA GA EGFR19R 5′GAG AAA AGG TGG GCC TGA G
EGFR 20 F 5′CAT GTG CCC CTG CTT CTG EGFR 20R 5′GAT CCT GGT TCC TTA TCT CC
EGFR21F 5′CCT CAC AGC AGG GTC TTC TC EGFR21R 5′CCT GGT GTC AGG AAA ATG CT
KRAS2F 5′GTG TGA CAT GTT CTA ATA TAG TCA KRAS2R 5′GAA TGG TCC TGC ACC AGT AA
KRAS3F 5′CCA GAC TGT GTT TCT CCC TTC KRAS3R 5′TGC ATG GCA TTA GCA AAG AC
The different exons of KIT, PDGFR, EGFR and KRAS are written in bold letters.
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as spindle-shaped and epithelioid cells were observed. Oc-
casionally, squamoid or spindle-shaped epithelial cells
with whorls resembling Hassall’s corpuscles were noticed.
The cytoplasm of the tumor cells was pale and nuclei were
clearly evident and slightly oval (see Figure 1A - F).
Immunohistochemistry
All CASTLE cases expressed CD5 in a moderate to
strong reaction and CD117 in predominantly weak to
moderate intensity in the epithelial component. Only in
one case a strong staining signal for CD117 could be de-
tected. (see Figure 1G +H). Staining with CK5/6 showed
weak to strong reactions in all samples (see Figure 1I).
EGFR showed a strong reactivity in three, weak staining
intensity in two samples and no staining pattern in one
case (see Figure 1J). COX-2 was detected positively in
all cases with mainly moderate expression patterns (seeTable 2 Patient characteristics and tumor progression
No. Stage Therapy
1 pT4, N1b (18/21), MX, R0 Total thyroidectomy, left central neck dissect
nerve and the left internal jugular vein, chem
Tumorectomy, bilateral neck dissection, trans
2 pT3, N0 (0/5), MX, R0 Thyroidectomy, cervico-central lymphadenec
3 pT3, N0, MX Subtotal thyroidectomy, local telecobaltthera
4 pT2, N0 (0/7), MX Hemithyroidectomy right, then restthyroidec
compartment, radiation of the thyroidbed (5
5 pT3, N1 (1/19), MX En bloc resection with the right lobe, neurol
dissection right, supraclavicular cervical latera
6 pT4a, N1 (1/5), M0, R0 Total thyroidectomy, neck dissection, radiatio
No. case number; Stage TNM classification.Figure 1 K). The expression of Ki67 showed varying re-
sults between 2% and 85%. The staining results for
CD117, EGFR, COX-2 and Ki67 are shown summarized
in Table 3. All cases were negative for calcitonin, thyro-
globulin and TTF-1 (Figure 1L).
Mutational analysis of KIT, PDGFR-α, EGFR, KRAS
Mutational analysis of KIT, PDGFR-α, EGFR and KRAS
was possible in only 4 cases due to inapplicable DNA in
case number 2 and 3.
Mutation analysis of all four investigated cases re-
vealed the absence of an activating mutation in the
PDGFR-α gene of exon 10, 12, 14 and 18. Nevertheless,
in all four cases a silent single nucleotide polymorphism
with a base substitution (CCA > CCG) in exon 12 at
codon 567 (p.P567P) of the PDGFR-α gene was ob-
served. This change has already been described in the
SNP database with the number rs1873778 (Figure 2A).Progression
ion, resection of the left recurrent laryngeal




tomy No recurrence (time of
observation: 36 months)
py of the neck (60 Gy) No recurrence (time of
observation: 19 months)
tomy, microdissection of the cervicocentral
9,4 Gy)
No recurrence (time of
observation: 15 months)
ysis N.laryngeus recurrens right, neck
l dissection, radiation (50 Gy)
No recurrence (time of
observation: 17 months)
n of the neck region (50 Gy) No recurrence (time of
observation: 22 months)
Figure 1 HE and immunohistochemical stainings. A-F. HE staining case 1–6. A. HE case 1, B. HE case 2, C. HE case 3, D. HE case 4, E. HE case 5,
F. HE case 6. G-L. Immunohistochemical staining case 1–6 for CD5, CD117, CK5/6, COX-2, EGFR and TTF-1. G. CD5 case 1. H. CD117 case 5. I. CK5/6 case 4.
J. EGFR case 6. K. COX-2 case 2. L. TTF-1 case 3.
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ism with a base substitution (CAG > CAA) in the EGFR
gene of exon 20 at position 787 (p.Q787Q) was ob-
served, which has also already been described in the
SNP database with the number rs1050171 (Figure 2B).
No mutation associated with drug sensitivity in the hot-
spot exons 18, 19, 20 and 21 was detected. No patient
had detectable sequence variants for KIT in the hotspot
region of exon 9, 11, 13 and 17. Also no sequence vari-
ants were found in the sequenced exons of the KRAS
gene (Table 4).Table 3 Immunohistochemical expression pattern
No. CD117 EGFR COX-2 Ki67 (%)
1 1 1 2 17
2 2 3 2 7
3 1 0 3 2
4 1 3 1 12
5 3 1 2 53
6 2 3 2 85
No. case number; 0 no staining, 1 weak, 2 moderate, 3 strong reaction intensity.Discussion
CASTLE tumors are rare malignant tumors occurring in
the thyroid, but the prognosis and the concomitant long
term survival rate is better than for other aggressive ad-
vanced thyroid neoplasms [1,2,5]. Among other things
and according to the so far largest study of CASTLE-
tumors comprising 25 cases [4,6] a significant number
may have been incorrectly classified, especially as squa-
mous cell carcinoma of the thyroid. In this study Ito
et al. showed a survival rate of 90% after 5 years and
82% after 10 years. Patients without lymph node metas-
tasis had an overall survival rate of 100% after 5 years,
those with lymph node metastasis 76% after 5 and 57%
after 10 years. One of our patients with initial lymph
node metastasis had recurrence after 2 months. No recur-
rence during an observation period of up to 73 months
occurred in the other patients. Interestingly, the expres-
sion of Ki67 showed varying results between 2% and 85%,
but could not be linked to the presence of lymph node
metastases or advanced tumor stages, as the only case in
which a tumor recurrence was observed showed a low
proliferation rate (compared to e.g. striking 85% in case
Figure 2 SNPs in PDGFR and EGFR genes. A. Forward chromatogram showing c.A1701G, predicting p.P567P in the PDGFR gene (db SNP= rs1873778).
B. Forward chromatogram showing c.G2361A, predicting p.Q787Q in the EGFR gene (db SNP = rs1050171).
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period of 22 months).
Because a diagnosis of CASTLE is difficult before re-
section of the tumor, patients are usually treated accord-
ing to the standards of thyroid gland carcinoma with








PDGFR-α 10 - - 4 wild type -
12 c.A1701G p.P567P 4 SNP rs1873778
14 - - 4 wild type -
18 - - 4 wild type -
EGFR 18 - - 4 wild type -
19 - - 4 wild type -
20 c.G2361A p.Q787Q 3 SNP rs1050171
20 - - 1 wild type -
21 - - 4 wild type -
KRAS 2 - - 4 wild type -
3 - - 4 wild type -
KIT 9 - - 4 wild type -
11 - - 4 wild type -
13 - - 4 wild type -
17 - - 4 wild type -
No. Number of patients; dbSNP http://www.ncbi.nlm.nih.gov/SNP/; SNP single
nucleotide polymorphism; Nucleotide alt. Nucleotide alteration; Amino acid
subst. Amino acid substitution.or without neck dissection. Depending on the tumor en-
tity and stage postoperative therapy is often indicated. 5
of our patients underwent radiotherapy, 1 combined
radiochemotherapy.
We have recently described chromosomal imbalances
in CASTLE similar to those found in thymomas and
thymic carcinomas [7]. Given the morphological, im-
munohistochemical and genetic similarities with thymic
carcinomas, it seems reasonable to assume that treat-
ment of advanced CASTLE should follow the guidelines
for thymic tumors and patients may benefit also from
evolving therapeutic options for patients with thymic
tumors [8-13].
CD117 is expressed in about 86% of thymic carcin-
omas [14], but KIT gene mutations are uncommon. So
far, only few cases of metastasizing thymic carcinoma
with an activating KIT mutation and a partial response
to treatment with Imatinib have been described [15,16].
In our analysis, all CASTLE tumors showed positive
staining results for CD117, but no mutations of the KIT
gene.
Membrane associated EGFR expression has been seen
in thymomas as well as in thymic carcinomas. Girard
summarized eight studies [17], which investigated EGFR
expression levels in thymic malignancies [18-25] using
immunohistochemistry. In this meta-analysis, EGFR was
overexpressed in 70% of thymomas and 53% of thymic
carcinomas, but there was no correlation between EGFR
expression and thymic tumor type. Activating EGFR mu-
tations seem to be exceptionally rare in thymic carcin-
omas with only few reported EGFR missense mutations
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case) [23,26]. In the present series, five tumors showed
weak to strong immunohistochemical staining results for
EGFR. Two of the four cases, in which DNA-extraction
was successful, showed a weak positivity for EGFR, the
other two cases showed a strong signal. In three cases mu-
tational analysis revealed a single nucleotide polymorph-
ism (SNP) in the EGFR gene of Exon 20 (p.Q787Q), but
no activating EGFR gene mutation could be found.
It has been shown that a therapeutic effect can be seen
after the use of EGFR-inhibitors in non-small cell lung
cancers, even if there is no activating mutation in the
EGFR gene [27]. In a small series of advanced thymic tu-
mours only a slight therapeutic effect could be demon-
strated with Gefitinib [28].
Randomised clinical trials have demonstrated the po-
tential of COX-inhibitors in tumor prevention [29].
Malka et al. showed that inhibition of COX-2 could play
a possible therapeutic role in other tumor entities, for
instance hepatocellular carcinoma [30]. In particular, the
combination of COX-2 inhibitors and EGFR-inhibitors
seems to increase the therapeutic effect in colon or cer-
vical carcinoma [31-34]. COX-2 is frequently upregu-
lated in thymomas and thymic carcinomas [11,12]. In
our study all tumors expressed COX-2 raising the possi-
bility to use COX-2 inhibitors in advanced cases.
Although in our investigation all four cases showed
SNPs in the PDGFR-α gene of exon 12, no activating
mutations in the PDGFR-α gene and no mutations in
Codon 12 and 13 of the KRAS gene were detected.
Conclusion
As already mentioned above, CASTLE shows some simi-
larity to thymic carcinoma. However, in the latter targeted
therapy is difficult and somehow limited in advanced tu-
mors as there are only few reported cases in which targeted
therapy was of some therapeutic benefit. Ströbel et al., for
example, suggest that in cases with advanced thymic car-
cinoma treatment with the multi-kinase inhibitor Sunitinib,
that targets VEGFR1–3, PDGFR-α, c-KIT, FLT3, colony
stimulating factor-1 (CSF1) and the RET receptor, is more
effective than therapeutic regimes using single-target mo-
lecular therapies like Gefitinib, even though there are no
activating mutations in the EGFR, KIT and PDGFR-α gene
[35]. In conclusion, our data may indicate a potential for
targeted therapies, but if these therapeutic strategies are of
benefit in CASTLE remains to be determined.
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